Leadership & Pay ·
NovaBridge Biosciences held its Annual General Meeting on September 8, 2026, with shareholders representing…
IMABNovaBridge Biosciences
NovaBridge Biosciences held its Annual General Meeting on September 8, 2026, with shareholders representing approximately 44.8% of outstanding shares present. The company removed Ms. Xin Liu from her position as a director with immediate effect following an ordinary resolution vote of 107,925,508 in favor and 13,313,327 against. This executive departure constitutes a material governance change affecting the company's leadership structure. NovaBridge Biosciences operates in the biotechnology industry, focusing on drug discovery and development.